24 results about "Acute infection" patented technology

The invention discloses a toxoplasma gondii double-gene deletion attenuated vaccine strain as well as a construction method and application thereof. The toxoplasma gondii double-gene deletion attenuated vaccine strain is constructed by deleting a ku80 gene and a CDC14 gene on the basis of a toxoplasma gondii type II PLK strain, and is named as PLK [delta] TgKu80 [delta] TgCDC14 ([delta] CDC14 for short), and experimental results show that the pathogenicity of the strain is remarkably reduced after the CDC14 gene is knocked out. In order to further explore the immune protection effect on toxoplasma gondii acute infection mice, secondary acute infection is carried out on mice immunized with delta CDC14 strains, and the result shows that compared with non-immunized group mice, no immunized mice die within 30 days, and all non-immunized mice die within 13 days. Therefore, the double-gene deletion attenuated vaccine strain has the potential of being used as a vaccine, and an effective technical means is provided for preventing toxoplasma gondii infection.

The invention relates to the field of medical treatment, and discloses a sepsis risk prompt detection method based on model prediction, which comprises the following steps of: collecting a clinical blood sample of an acute infection patient, matching gene expression characteristics of the clinical blood sample with a database through gene target analysis, primarily screening out gene expression data obviously related to sepsis, and comparing the gene expression data with the database; according to the gene expression data of the marked sepsis patient samples and the gene expression data of the non-sepsis patient samples, gene expression differences are obtained, differential gene data and clinical data are established, a machine learning algorithm model is trained, and a sepsis recognition model is obtained; differential gene detection data related to sepsis is input into a sepsis recognition model for prediction, a sepsis recognition result is output, the sepsis recognition result and detection data of a sepsis rehabilitation patient are compared and analyzed, a model prediction effect is evaluated, and early warning is performed on prediction and evaluation results. The accuracy of model prediction is improved, and the prediction capability of the model is enhanced.

The application discloses a recombinant T cell with a knocked-out STARD7 gene and an application thereof, relates to the technical field of immune cells, and discloses that the recombinant T cell does not contain a functional STARD7 gene, or a biological function of a STARD7 gene product of the recombinant T cell is inhibited. In the application, the STARD7 is knocked out in T cells by means of CRISPR-Cas9 gene editing in an early stage of acute infection of mice, differentiation of SLECs is significantly damaged, and the proportion and quantity of MPECs are increased to a certain extent; therefore, the knockout of the STARD7 can be used as a treatment method for increasing the quantity of MPECs and regulating immune cells, so as to resist acute infection caused by external pathogens and promote the maintenance of memory cells existing in the body for a long time.

The inventions relate to compounds and compositions comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and methods for the treatment of post-acute infection disorders, including long COVID, long flu, and post-treatment Lyme disease syndrome.

The invention belongs to but not limited to the technical field of human and animal health diagnostics, and discloses a binding molecule for acute infection diagnosis adapted to a point-of-care (POC) scene, an acute infection diagnosis system and a kit. The binding molecule is an antibody, a nano antibody or an aptamer (preferably not combined with IgM) which is specifically combined with a J chain of dIgA, steric hindrance and conformation rearrangement are avoided by combining the J chain, and the flexibility of a compound is kept so as to efficiently combine with an antigen; the diagnostic system and the kit are adapted to POC scenarios (such as lateral flow test strips). The problems that POC deployment is difficult, RAT sensitivity is low and dIgA detection efficiency of CSC is low in existing NAT are solved, and the kit has the advantages of being low in cost, high in specificity and good in stability, can be used for rapid diagnosis of multiple acute infections such as measles and syphilis, fills up related technical gaps and has high commercial value.

The invention belongs to the technical field of kit preparation, and particularly relates to preparation and application of a pertussis acute infection detection test strip based on double-T-line immunochromatography. The amino acid sequence of the recombinant protein provided by the invention is as shown in SEQ ID NO. 1. The recombinant protein is used as an antigen to prepare a double-T-line test strip for detecting the pertussis IgG antibody, and the test strip is extremely simple and convenient to operate, rapid in detection and visual and reliable in result interpretation, has excellent sensitivity, specificity and stability, can realize semi-quantitative detection of the pertussis IgG antibody, and can be used for detecting the pertussis IgG antibody. The pertussis IgG antibody detection method solves the problems that an existing pertussis IgG antibody detection method is complex in operation, long in consumed time and high in cost, whether the antibody level is in an immune protection state or an acute infection state can be preliminarily judged according to the color development condition of a detection line, and powerful support is provided for clinical pertussis infection diagnosis and disease prevention and control.

This invention discloses the construction of a Toxoplasma gondii progesterone-responsive kinase-deficient strain and its application as a live attenuated vaccine. The Toxoplasma gondii progesterone-responsive kinase-deficient strain is derived from Toxoplasma gondii RHΔ... ku80 As a maternal strain, the gene-editing technology was used to knock out the enzyme encoding progesterone-responsive kinase. prk The gene-deleted strain was named RHΔ ku80 Δ prk Experiments have shown that RHΔ ku80 Δ prk The virulence of the strain was significantly reduced, and immunized mice showed good immunoprotection against acute infection with highly virulent and moderately virulent Toxoplasma gondii strains, and significantly inhibited brain cyst formation in a chronic infection model. Therefore, RHΔ ku80 Δ prk This invention has potential application value as a live attenuated vaccine against Toxoplasma gondii. It has significant application prospects.

The application discloses a method for constructing an animal model of chronic pulmonary infection / persistence of Acinetobacter baumannii, and belongs to the technical field of infectious disease animal model construction and microbial preparation. Compared with the acute infection and rapid clearance mode formed by directly inoculating free bacteria, the live bacterial microspheres prepared in the application can prolong the local exposure and detectable time of Acinetobacter baumannii in the lung, so that the Acinetobacter baumannii is more likely to form a low-load, long-term persistence pulmonary infection state, thereby providing a more stable experimental platform for the mechanism of chronic infection formation, host immune dynamic change and related intervention evaluation.

A system and method for detecting a persistent change in health following an acute infection. A set of physiological parameters, acquired over at least a period prior to an acute infection and a period following the acute infection, are obtained for a subject, and a period during which the subject had the acute infection is identified. The set of physiological parameters are processed to determine whether the subject has a persistent change in health following the acute infection.

The invention discloses application of a compound triclosan in preparation of a medicine for treating toxoplasmosis. The medicine is used for inhibiting toxoplasmosis proliferation. The medicine is used for relieving pathological injuries of one or more organs caused by toxoplasma gondii infection, and the organs comprise the heart, the liver, the spleen, the kidney and the brain. The medicine is used for protecting brain tissues or penetrating a blood brain barrier to treat toxoplasma gondii infection of a central nervous system; the medicine comprises a therapeutically effective amount of triclosan and a pharmaceutically acceptable carrier or auxiliary material, the dosage form of the medicine is an oral preparation; the application has the beneficial effects that the broad-spectrum antibacterial agent triclosan is proved to have a new application of remarkably treating toxoplasmosis for the first time, in-vivo and in-vitro experiments prove that triclosan can effectively inhibit the proliferation of toxoplasmosis, the effect is dose-dependent, and in an acute infection mouse model, triclosan can remarkably improve the survival rate of mice and reduce the ascites insect-bearing quantity, so that the effect of treating toxoplasmosis is achieved. The pathological injury of multiple organs such as heart, liver, spleen and kidney can be relieved.

The invention discloses a novel application of Etravirine in the prevention or treatment of infection of Listeria monocytogenes (Listeria monocytogenes), and particularly discloses a novel application of Etravirine in the prevention or treatment of infection of Listeria monocytogenes (Listeria monocytogenes). Through allosteric inhibition of PlcA protein activity and enhancement of cell autophagy flux and bacterial ubiquitination labeling by etravirine, the bacterial clearance rate in an infection model is significantly improved, no direct inhibition effect on bacterial growth exists, and the risk of drug resistance generation is reduced. It is further proved that etravirine has a good treatment effect on listeria infection by establishing a mouse acute infection model. Therefore, as a virulence factor PlcA inhibitor, etravirine can obviously reduce the pathogenicity of Listeria monocytogenes, and has important significance for developing a novel administration scheme for resisting Listeria monocytogenes infection.

The inventions relate to compounds and compositions comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and methods for the treatment of post-acute infection disorders, including long COVID, long flu, and post-treatment Lyme disease syndrome.

The invention provides an application of a mycobacterium tuberculosis antigen Rv1471 in preparation of drugs or vaccines for preventing and / or treating diseases caused by mycobacterium infection. In a cell model, the antigen Rv1471 can promote the maturation of phenotypes and functions of macrophages, and also can mediate training immunity. On the basis, a subunit protein vaccine for expressing the antigen Rv1471 is further constructed. In a mouse immune model, the immunogenicity of the subunit protein vaccine expressing the antigen Rv1471 in a mouse which is not immunized by BCG is measured, and the subunit protein vaccine can promote antigen-specific T cell immune response. In a cell model and an acute infection mouse model, the antigen Rv1471 can provide an effective protection effect against mycobacterium tuberculosis infection. Therefore, the antigen Rv1471 and the subunit vaccine thereof are expected to become a novel preventive / therapeutic tuberculosis vaccine.

The invention discloses a next-generation sequencing kit for detecting respiratory tract pathogenic bacteria based on multiple primer amplification, and belongs to the technical field of microbiological detection. The nucleotide sequence of the primer group is as shown in SEQ ID NO.1-2670. The primer group is used for detecting classification of various pathogens, drug-resistant gene loci and host infection reaction up-regulation genes by adopting a targeted high-throughput sequencing (tNGS) technology. Compared with metagenome high-throughput sequencing (mNGS), the method has the advantages that the detection sensitivity is greatly improved, DNA and RNA processes can be considered at the same time, the detection time is greatly shortened, and the method has the characteristics of accuracy, practicability, uniqueness, leading edge, time saving, money saving and the like; especially, detection on host infection reaction up-regulation genes can be used for distinguishing pathogenic bacteria or conditioned pathogenic bacteria in samples, distinguishing whether acute infection causes belong to infectivity or non-infectivity, is unique in similar metagene products, and is compared with a metagene mNGS method for clinical specimen comparison verification. And the kit is accurately applied to etiological diagnosis of respiratory system infection.

The present disclosure relates to methods of treating Alzheimer's disease, diseases and / or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.

The application is a kind of nanoscale enzyme multifunctional composite hydrogel and its preparation method and application, belonging to the field of biological medicine technology. In view of the problem that the existing materials or drugs have poor treatment effect on infected wound, the application comprises the following steps: preparing solution A and solution B respectively, standby, preparing Cu-TCPP-Mn nanosheet, obtaining Cu-TCPP-Mn nanodot after further treatment, adding the activated Cu-TCPP-Mn nanodot into solution A to obtain mixed solution C with a concentration of 5 mu g / mL, adding the activated PRP solution into solution B to obtain mixed solution D with a concentration of 100 mu g / mL, and mixing the mixed solution C and the mixed solution D in equal volume to obtain CHPM composite hydrogel. The CHPM composite hydrogel can effectively reduce the oxidative stress level of acute infected wound tissue, provide a suitable oxidative microenvironment for PRP to play a role in promoting angiogenesis, and accelerate the healing of acute infected wound.

The invention belongs to the technical field of biology, and particularly relates to an establishment method and application of a pigeon salmonella acute infection model. The establishment method comprises the following steps: infecting a squab by adopting pigeon source salmonella typhimurium obtained by separation and screening in a subcervical multi-point injection manner, and preparing to obtain a pigeon salmonella acute infection model; the pigeon source salmonella typhimurium is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on August 25, 2025, and the preservation number of the pigeon source salmonella typhimurium is CGMCC N0.35198. According to the establishment method, the technical problems of low success rate and poor replication rate of an existing modeling method are solved, the pigeon salmonella acute infection model established by the method improves the modeling success rate and uniformity, is long in disease course and stable, can assist in research and development of drugs for preventing and treating pigeon salmonella infection, and can realize effective and objective evaluation of the drug effect.

The application belongs to the technical field of biotechnology, and particularly relates to a recombinant antigen of American trypanosomiasis and a preparation method and application thereof. The application provides a recombinant antigen of American trypanosomiasis, wherein a plurality of neutralizing epitopes and complete amino acid sequences of Trypanosoma cruzi antigens are connected according to a specific order to construct a recombinant antigen capable of covering all stages of the life cycle of Trypanosoma cruzi. The recombinant antigen is complete in Chagas antibody recognition site coverage, can recognize and combine all types of antibodies in the Chagas chronic and acute infection period, and is not easily interfered by other substances in serum, and is high in specificity.

This disclosure belongs to the field of biopharmaceutical technology, and specifically relates to a biomimetic nanoparticle that targets and activates neutrophils, its preparation method, and its application. This disclosure provides a biomimetic nanoparticle that targets and activates neutrophils. The biomimetic nanoparticle consists of a nanocore and an endothelial cell membrane covering the surface of the nanocore. The endothelial cell membrane is an endothelial cell membrane expressing ICAM-1. The biomimetic nanoparticle provided by this disclosure has advantages such as specific targeting of neutrophils, good biocompatibility, long circulation time, high efficiency of inflammatory accumulation, and integrated diagnosis and treatment. It can precisely regulate excessive neutrophil activation, significantly improving the therapeutic effect and safety for diseases such as acute infections and chronic wounds.

The invention discloses a method for constructing an acinetobacter baumannii chronic pulmonary infection / retention animal model, and belongs to the technical field of infectious disease animal model construction and microbial preparation preparation. Compared with a quick elimination mode after acute infection formed by direct inoculation of free bacteria, the viable bacteria microspheres prepared by the invention can prolong local exposure and detectable time of acinetobacter baumannii in the lung, so that the acinetobacter baumannii can form a low-load and long-term pulmonary infection state more easily; therefore, a more stable experimental platform is provided for chronic infection formation mechanism, host immune dynamic change and related intervention evaluation.

Described is a vaccine for use in actively immunising a subject against an infectious disease or a malignant disease, said vaccine comprising: (a) an antibody against an antigen correlated with said infectious disease or malignant disease; or (b) an Fc-containing fusion protein comprising an Fc part of an antibody fused to an antigen correlated with said infectious disease or malignant disease, wherein said Fc part is capable of binding a receptor present on or in an antigen presenting cell (APC) selected from the group consisting of Type I: activatory FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa, FcγRIIIb, and inhibitory FcγRIIb; and Type II: neonatal FcR (FcRn) and cytosolic TRIM21. Moreover, described is a vaccine for use in actively immunising a subject against an HSV-associated disease; and (a) wherein said antibody is an anti-HSV antibody and said subject suffers from an acute HSV-associated disease, preferably an acute HSV infection; or (b) wherein in said Fc-containing fusion protein comprising an Fc part of an antibody fused to an antigen, the antigen correlates with an HSV-associated disease.

The present invention relates to the field of medicine. The invention in particular relates to amide- derivatives of 2-hydroxy-2-methyl-4-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-butanoic acid and related compounds for treating post-acute infection syndromes such as long COVID. It was found that the compounds have beneficial effects in reducing symptoms of post-acute infection syndromes, such as post-exertional malaise and persistent fatigue.

The invention relates to the technical field of biological medicines, in particular to application of E3 ubiquitin ligase RNF219 in preventing or treating inflammatory diseases. The invention provides an application of a substance for inhibiting the activity of RNF219 protein or a substance for reducing the content of RNF219 protein in preparation of drugs for preventing or treating inflammatory diseases, especially drugs for preventing or treating sepsis and colitis. According to the application, a mouse acute infection model is constructed to prove that RNF219 defect inhibits the inflammatory reaction degree and inflammatory injury induced by LPS (Lipopolysaccharide); in a mouse with DSS-induced colitis, the RNF219 defect can delay the disease progress of the mouse colitis and improve the inflammatory phenotype of the mouse. Therefore, the function of the RNF219 in natural immune response is defined, and the RNF219 has important scientific significance on prevention and treatment of immune inflammation related diseases such as sepsis and inflammatory bowel diseases.

The application provides a lysophosphatidylcholine (LPC) kit with anti-coccidiosis effect, and discloses a diagnosis marker for Eimeria tenella infected chicken, which is characteristic phospholipid and sphingolipid molecules, and specifically phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and sphingomyelin (SM). Meanwhile, the application provides a medicine composition for improving the survival rate of chicks infected with Eimeria tenella, which is characterized by containing effective amounts of 18:2 LPA, 18:1 LPC, 22:0 LPC, 16:0 18:1 PC, 16:0 18:2 PC and d18:1 16:0 SM. The application screens characteristic phospholipid and sphingolipid molecules in the cecum tissue of chicken infected with Eimeria tenella for the first time, and verifies the curative effect of phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and sphingomyelin (SM) on acute infection of chicks with Eimeria tenella, which has great market development prospect.